Skip to Main content Skip to Navigation
Journal articles

Oral edelfosine lipid nanoparticles caused the regression of lung metastases in pre- clinical osteosarcoma animal models

Abstract : Osteosarcoma (OS) is the most frequent paediatric bone cancer, responsible for 9% of all cancer-related deaths in children. In this paper, a new strategy based on delivering edelfosine (ET) in lipid nanoparticles (LN) was explored in order to target the primary tumor and eliminate metastases. The in vitro and in vivo efficacy of the free drug, drug loaded into lipid nanoparticles (ET-LN) and doxorubicin (DOX) against osteosarcoma (OS) cells was analysed. ET and ET-LN decreased the growth of OS cells in vitro in a time- and dose-dependent manner. Interestingly, the uptake of ET and ET-LN was lower when OS cells were pre-treated with DOX. In vivo studies revealed that ET and ET-LN slowed down the primary tumour growth in two OS models. However, the combination of both drugs showed no additional anti-tumour effect. Importantly, ET-LN successfully prevented the metastatic spread of OS cells from the primary tumour to the lungs. On the whole, ET-LN are a promising candidate for OS chemotherapy.
Complete list of metadatas

Cited literature [24 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01803295
Contributor : Dominique Heymann <>
Submitted on : Wednesday, May 30, 2018 - 11:01:03 AM
Last modification on : Friday, June 19, 2020 - 1:40:17 AM

Identifiers

Collections

Citation

Yolanda González-Fernández, Hannah Brown, Ana Patiño-García, Dominique Heymann, María Blanco-Prieto. Oral edelfosine lipid nanoparticles caused the regression of lung metastases in pre- clinical osteosarcoma animal models. Cancer Letters, Elsevier, 2018, 430, pp.193 - 200. ⟨10.1016/j.canlet.2018.05.030⟩. ⟨inserm-01803295⟩

Share

Metrics

Record views

230

Files downloads

245